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Summary The aim of this audit was to ascertain outcomes for people who had taken
or who were still taking three ‘‘new generation’’ broad-spectrum antiepileptic drugs
(AEDs), namely lamotrigine, levetiracetam and topiramate.
Thirteen percent of people became seizure free and approximately, one-third had
a reduction of greater than 50% in their seizures. Two-thirds of people were still taking
their audit AED. In addition, approximately one-third of people with a learning
disability derived substantial benefit, although the rate of seizure freedomwas lower.
All three AEDs were most successful at treating primary generalised epilepsy and
least successful with symptomatic generalised epilepsy.
With some reservations the data suggests that levetiracetam and topiramate are
the most efficacious AEDs, but topiramate is the least well tolerated. These results
mean consideration of a ‘‘general prescribing policy’’ is important when using and
choosing these AEDs.
We conclude that lamotrigine, levetiracetam and topiramate are useful additions
to the armamentarium of AEDs.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Formany years, physicians had few choices for treat-
ing epileptic seizures.Within the past 15 years, many
‘‘new generation’’ antiepileptic drugs (AEDs) have
been introduced. The new agents have been shown in
clinical trials to offer similar efficacy compared with
older, more established AEDs.1,2 Some studies have
shown that the new agents offer important improve-
ments in safety and side effect profile.1,3
The three ‘‘new generation’’ AEDs studied in this
audit are lamotrigine, levetiracetam and topira-* Corresponding author. Tel.: +44 1484 647895.
E-mail address: neuroeducation@ntlworld.com (B. Chappell).
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doi:10.1016/j.seizure.2005.07.005mate, which are the most commonly prescribed
‘‘newgeneration’’ AEDs in theUnitedKingdom.4They
were chosen because they are all ‘‘broad spectrum’’,
in otherwords they are known to have some effect on
the vast majority of seizure types. Most clinical trials
of these AEDs initially investigated their efficacy for
localisation-related seizures with or without second-
ary generalisation.5—10 There is trial data for lamo-
trigine and topiramate in primary generalised
epilepsy,11—14 but as yet the data for levetiracetam
is mainly from experience in clinical practice.15,16
This means the former two AEDs have wider licences
than the latter. Nevertheless, this study reports on
usage of all three AEDs in a wide range of seizure
types.by Elsevier Ltd. All rights reserved.
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Chart 1The present data available on usage of these three
AEDs in everyday adult UK district hospital clinical
practice is limited.16—24 It is, therefore, important
that knowledge is expanded of their usage in a ‘‘gen-
eral’’ epilepsy population, as the results are likely to
be different from the trial data. This study aims to
contribute to the expansion of this knowledge base.
Methods
Hospital patient notes were searched on three sepa-
rate occasions for people who were taking or who
had taken one of the three audit AEDs. The same
search critieria were used on each occasion. In the
Results section we, therefore, refer to the number
of exposures to the audit AEDs as opposed to the
number of people.
The three patient note searches were undertaken
approximately 2 years post the United Kingdom
licensing of each audit AED. Lamotrigine was, there-
fore, audited first, topiramate second and levetir-
acetam third. Some of the cohort had been taking
their audit AED much longer than 2 years, because
they were initiated on a particular AED pre-licence.
Some people have taken more than one of the
audit AEDs and will, therefore, be counted in the
data on more than one occasion.
The following categories of information were
recorded: audit drug, dose attained on audit drug,
name, hospital number, sex, age, age of seizure
onset, whether the person had learning disabilities,
whether the person had primary generalised, symp-
tomatic generalised or a localisation-related onset
epilepsy, outcome for seizure frequency compared to
baseline, side effects, whether the person is continu-
ing on the audit AED and if not the length of time
before the person stopped taking the audit AED.
Results were recorded in both EXCEL and SPSS
11.0 for Windows. Analysis was completed using
SPSS. Where groups of people were compared for
significance the statistical test used was chi-square
with one exception, for ‘‘time to drop out’’ the
Kaplan—Meier test was used.
Results
Characteristics of the exposures to an
audit AED
Two hundred and ten exposures (45%) were in males
and 258 (55%) were in females. Sixty-three (14%)
exposures were in those aged 20 years and under,
397 (85%) were 21—65 years old inclusive and 8 (2%)
were 66 years and over.When seizures started, 372 (80%) of the people
exposed were aged 20 years and under, 94 (20%)
were 21—65 years old inclusive and 0 (0%) were 66
years and over.
Ninety-three exposures (20%) were in people who
had primary generalised epilepsy, 57 (12%) had
symptomatic generalised epilepsy and 317 (68%)
had localisation-related epilepsy.
When audited 245 (52%) were taking lamotrigine
(LTG), 94 (20%) were taking topiramate (TPM) and
129 (28%) were taking levetiracetam (LEV).
The following were the doses attained for each of
the audit AEDs:AED Minimum Maximum Mean Standard
deviationLamotrigine 25 1000 291 178.2430
Topiramate 25 900 349 218.8819
Levetiracetam 500 4000 1994 690.6640Ninety-six exposures (20%) were in people who
had learning disabilities.
The following bar chart shows the number of AEDs
people were already taking when their audit AED
was added (Bar Chart 1).
This second chart shows the number of AEDs the
person had already taken at sometime before the
introduction of the audit AED (Bar Chart 2).
Cohort characteristics and each drug
audited (N = 468)
To try and ascertain whether the exposures to each
audit AED were fairly similar, all exposures were
compared for their basic characteristics against the
drug they were taking at the point of audit.
The groups were similar in the case of age, sex,
age of onset, symptomatic generalised epilepsy,
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Table 1 Drug efficacy (N = 451).
Seizure
frequency
Number Percent Valid
percent
Cumulative
percent
Seizure free 58 12.4 12.9 12.9
>50%
decrease
92 19.7 20.4 33.3
1—50%
decrease
159 34.0 35.3 68.5
No efficacy 136 29.1 30.2 98.7
Seizures
worse
6 1.3 1.3 100.0
Total 451 96.4 100.0
Missing
system
17 3.6
Total 468 100.0
Chart 2localisation-related epilepsy and the number with a
learning disability.
There was significant difference between each
exposure group in that those with primary general-
ised epilepsy were more likely to be prescribed leve-
tiracetam (p < .029). There were also significant
differences in the number of AEDs exposed people
were already taking when the audit AED was added
(Bar Chart 1) and the number of AEDs exposed people
had already taken at sometime before the introduc-
tion of the audit AED (Bar Chart 2).
The latter two pieces of data suggested that
the lamotrigine group possibly had less severe
epilepsy. For ‘‘AEDTAKE’’ the lamotrigine group
were taking less other AEDs when it was added
than the topiramate group ( p < .001) and the
levetiracetam group ( p < .001). This was also
the case for ‘‘AEDPRIOR’’ where the lamotrigine
group had taken less other AEDs before it was
introduced: topiramate ( p < .001); levetiracetam
( p < .001). The picture was much less clear whenTable 2 Time to ‘‘drop-out’’ (N = 155).
Time Number Percent
<3 month 25 16.0
4—6 months 66 42.3
7—12 months 29 18.6
13—24 months 16 10.3
>24 months 19 12.2
Total 155 99.4
Missing system 1 0.6
Total 156 100.0
Table 3 Primary generalised epilepsy (N = 88).
Seizure-free >50% decrease 1
Number 17 19 2
Percentage within (%) 19.3 21.6 3comparing the topiramate and levetiracetam
groups. In the case of ‘‘AEDTAKE’’ the topiramate
group were taking less other AEDs when it was
added ( p < .001), but for ‘‘AEDPRIOR’’ the levetir-
acetam group had tried less other AEDs before it
was introduced ( p < .040).
Drug efficacy (N = 451)
Table 1 outlines the seizure outcome for 451 of the
exposures, using commonly agreed markers. Sei-
zure-free is defined as no seizures for 6 months or
longer.
People exposures continuing on an audit drug
(N = 468)
Three hundred and twelve (67%) were continuing on
their audit drug and 156 (33%) were not, due to
either a lack of efficacy or side effect problems.Valid percent Cumulative percent
16.1 16.1
42.6 58.7
18.7 77.4
10.3 87.7
12.3 100.0
100.0
—50% decrease No efficacy Seizures worse Total
9 22 1 88
3.0 25.0 1.1 100.0
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Table 4 Symptomatic generalised epilepsy (N = 56).
Seizure-free >50% decrease 1—50% decrease No efficacy Seizures worse Total
Number 5 13 20 16 2 56
Percentage within (%) 8.9 23.2 35.7 28.6 3.6 100.0
Table 5 Localisation-related epilepsies (N = 306).
Seizure-free >50% decrease 1—50% decrease No efficacy Seizures worse Total
Number 36 58 110 99 3 306
Percentage within (%) 11.8 19.0 35.9 32.4 1.0 100.0Time to ‘‘drop-out’’ (N = 155)
In the case of the exposures where an audit drug had
been stopped, Table 2 outlines the length of time it
took for this to occur.
Drug efficacy and epilepsy type
Tables 3—5 outline seizure outcome for the three
chosen categories.
Levetiracetam efficacy and epilepsy type
(N = 126)
For exposures in people who had primary general-
ised epilepsy six out of 35 (17%) became seizure-Table 6 Lamotrigine (LTG) vs. levetiracetam (LEV) vs. top
AED Seizure-free >50% decrease 1—50%
Lamotrigine
Number 24 40 65
% within 10.2 17.0 27.7
Topiramate
Number 20 12 51
% within 22.2 13.3 56.7
Levetiracetam
Number 14 40 43
% within 11.1 31.7 34.1
Total
Number 58 92 159
% within 12.9 20.4 35.3
Value
Chi-square tests: lamotrigine (LTG) vs. levetiracetam (LEV)
Pearson chi-square 21.213
Value
Chi-square tests: lamotrigine (LTG) vs. topiramate (TPM)
Pearson chi-square 49.029
Value
Chi-square tests: levetiracetam (LEV) vs. topiramate (TPM)
Pearson chi-square 24.954
Comparison of drug efficacy.free. In the case of localisation-related epilepsy, the
figure was eight out of 80 (10%) for those becoming
seizure-free and for symptomatic generalised epi-
lepsy, zero out of 12 (0%).
Comparison of drug efficacy
Table 6 outlines the efficacy of each audit AED.
Comparison of ‘‘drop-out’’
Table 7 outlines how many of the exposures are still
taking their audit AED or not.iramate (TPM) (N = 451).
decrease No efficacy Seizures worse Total
100 6 235
42.6 2.6 100.0
7 0 90
7.8 0.0 100.0
29 0 126
23.0 0.0 100.0
136 6 451
30.2 1.3 100.0
d.f. Asymp. sig. (two-sided)
4 0.000
d.f. Asymp. sig. (two-sided)
4 0.000
d.f. Asymp. sig. (two-sided)
3 0.000
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Table 7 Lamotrigine (LTG) vs. levetiracetam (LEV) vs.
topiramate (TPM) (N = 468).
AED Continuing Not continuing Total
Lamotrigine
Number 160 85 245
% within 65.3% 34.7% 100.0%
Topiramate
Number 45 49 94
% within 47.9% 52.1% 100.0%
Levetiracetam
Number 107 22 129
% within 82.9% 17.1% 100.0%
Total
Number 312 156 468
% within 66.7% 33.3% 100.0%
Value d.f. Asymp. sig. (two-sided)
Chi-square tests: lamotrigine (LTG) vs. levetiracetam
(LEV)
Pearson
chi-square
12.874 1 0.000
Value d.f. Asymp. sig. (two-sided)
Chi-square tests: lamotrigine (LTG) vs. topiramate
(TPM)
Pearson
chi-square
8.638 1 0.003
Value d.f. Asymp. sig. (two-sided)
Chi-square tests: levetiracetam (LEV) vs. topiramate
(TPM)
Pearson
chi-square
30.823 1 0.000
Comparison of ‘‘drop-out’’.Comparison of time to ‘‘drop out’’ (N = 155)
The following is a Kaplan—Meier graph comparing
the drop-out time of the three audit AEDs.
Exposures in those people with learning
disabilities (LDs)
Table 8 outlines the seizure outcome using com-
monly agreed markers.
Table 9 outlines the number still taking their
audit AED.
Discussion
This is one of the largest cohorts of people with
epilepsy taking a new generation antiepileptic
reported from a United Kingdom district general
hospital. The cohort is not strictly similar to those
usually found in neurosciences outpatients as theTable 8 Efficacy of AEDs in those with LDs.
Seizure frequency Number Percent Valid percent Cumulative percent
Seizure-free 5 5.2 5.3 5.3
>50% decrease 28 29.2 29.5 34.7
1—50% decrease 35 36.5 36.8 71.6
No efficacy 24 25.0 25.3 96.8
Seizures worse 3 3.1 3.2 100.0
Total 95 99.0 100.0
Missing system 1 1.0
Total 96 100.0
Table 9 Number of people with LDs continuing to take their audit AED.
Frequency Percent Valid percent Cumulative percent
Continuing 71 74.0 74.0 74.0
Not continuing 25 26.0 26.0 100.0
Total 96 100.0 100.0
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is involved with both a joint learning disability clinic
and antiepileptic drug trials. This means that the
cohort is biased towards the more severe epilepsies
in comparison toa standardneurosciencesoutpatient
population. It is probably, therefore, logical to sug-
gest that the outcomes identified may be improved
upon in general neurosciences outpatient clinics.
The efficacy and usefulness of new generation
antiepileptics has been challenged by some22 and
supported by others.1,15,16,25 This data would sug-
gest a useful role for lamotrigine, topiramate and
levetiracetam. Thirteen percent of the exposures to
an audit AED led to seizure freedom and 33% led to a
greater than 50% decrease. Sixty-seven percent of
the exposures were continuing to take their audit
drug, which virtually balances with the figure of 69%
of the exposures that had some sort of seizure
decrease, however, small. If people did stop taking
their audit drug, unsurprisingly, they were most
likely to do this in the first 6 months (nearly 60%
and nearly 90% within 12 months).
This study chose to have a simple regime for
classifying epilepsy type: primary generalised, symp-
tomatic generalised and localisation related. The
three audit drugs were much more likely to success-
fully treat primary generalised epilepsy. As yet, leve-
tiracetam does not have a licence for treating this
type of epilepsy, but this data suggests it is useful.
With this type of audit data, it is not generally
advisable to try and compare outcomes for the three
audit drugs. There are a number of reasons for this,
not least that by definition the group being treated
becomes more ‘‘resistant’’ to treatment with time,
i.e., many people in the levetiracetam group have
probably already been ‘‘resistant’’ to firstly lamo-
trigine and secondly topiramate before they receive
levetiracetam. For most of the core data (e.g. age,
sex, etc.) the three groups were similar, but people
were more likely to have primary generalised epi-
lepsy in the levetiracetam group. Whilst allowing for
these reservations comparison of the data on seizure
efficacy and ‘‘drop-out’’ would suggest that this
data is similar to others.15,16,21,26—29 Some studies
have reported worse outcomes, but it would appear
that their cohorts had more severe epilepsies.20,22
This data would suggest that topiramate is more
likely to stop seizures than the other two AEDs, but
in the case of levetiracetam it needs to be consid-
ered that the patient cohort is likely to be the most
resistant to treatment. As has been shown in other
studies this efficacy does have a downside, because
people are less likely to tolerate topiramate com-
pared with the other two AEDs.21,22,30
In the United Kingdom, both lamotrigine and
topiramate have very wide-ranging licences for dif-fering seizure types. This is not the case for levetir-
acetam. Data from this study would suggest that
levetiracetam has a wide spectrum of activity, being
probably as efficacious for primary generalised epi-
lepsy (17% seizure-free) as it is for localisation-
related epilepsy (10% seizure-free) in a population
previously resistant to treatment.
The cohort contained 96 exposures to an audit
AED in those with learning disabilities. People with
learning disabilities are usually more resistant to
treatment than others31 and this study confirmed
this. Only 5% of the exposures in this group led to
seizure freedom against 13% of those who did not
have learning disabilities. However, very interest-
ingly, when you group together exposures that
became seizure-free and those with a greater than
50% decrease in seizures, people with learning dis-
abilities responded in a similar way; 35% exposure
responders against 33%. This latter finding deserves
more investigation and further research.Conclusion
As 13% of the people exposures led to seizure free-
dom and approximately one-third had a reduction of
greater than 50% in their seizures in this study, the
conclusion has to be that lamotrigine, levetiracetam
and topiramate are useful additions to the arma-
mentarium of AEDs in a ‘‘general’’ population with
epilepsy. Approximately, one-third of the exposures
in people with a learning disability also had a sub-
stantial benefit, although the rate of seizure free-
dom was lower.
All three AEDs are most successful at treating
primary generalised epilepsy and least successful
with symptomatic generalised epilepsy.
With some reservations the data suggests that
topiramate is the most efficacious AED, followed by
levetiracetam, but the least well tolerated. These
results mean consideration of a ‘‘general prescribing
policy’’ is important when using and choosing these
AEDs. Is ‘‘power’’ to stop seizures more or less
important than ‘‘power’’ to avoid complications?
On balance, we prefer the latter in the pursuit of
high-quality long-term care.References
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